Skip to main content
Premium Trial:

Request an Annual Quote

Cephalon Expands Agreement with Pharsight

NEW YORK, Nov. 12-Cephalon will use Pharsight's modeling and simulation methods to investigate new applications for Provigil, its narcolepsy treatment, Pharsight said today.

 

Cephalon has used Pharsight's systems before during clinical trials to help determine appropriate drug dosage for the treatment of sleep disorders.

 

With the expanded agreement, Cephalon now plans to use Pharsight's modeling techniques to predict dosages for the treatment of attention deficit hyperactivity disorder.

 

Financial details of the expanded agreement were not disclosed.

 

For further details, see the company statement.

The Scan

Long COVID-19 Susceptibility Clues Contained in Blood Plasma Proteome

A longitudinal study in eBioMedicine found weeks-long blood plasma proteome shifts after SARS-CoV-2 infection, along with proteomic signatures that appeared to coincide with long Covid risk.

Tibetan Study Finds Adaptive Variant Influencing Skin Pigmentation

With a combination of phenotyping and genetic data, researchers document at PNAS a Tibetan-enriched enhancer variant influencing melanin synthesis and ultraviolet light response.

Domestication Linked to Nervous System Genes in Inbred Mouse Strains

Researchers highlighted more than 300 positively selected genes in domesticated mice, including genes linked to nervous system function or behavior in Genome Biology.

ALS Genetic Testing May Be Informative Across Age Ranges, Study Finds

Researchers in the journal Brain identified clinically actionable variants in a significant subset of older ALS patients, prompting them to point to the potential benefits of broader test use.